Symbols

DFTX

Definium·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DFTX

Definium Therapeutics, Inc.

A clinical stage neuropharmaceutical development company

Industry

Pharmaceutical

Established Date

Listing Date

04/27/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

105

Fiscal Year Ends

12-31

Website

www.definiumtx.com

Security Type

Common stock

Office address

One World Trade Center, Suite 8500, New York, New York 10007

Business

Introduction

Definium Therapeutics, Inc., was incorporated in 2010 under the laws of British Columbia. They are a late-stage clinical biopharmaceutical company developing new product candidates to treat brain health disorders. Their mission is to forge a new era of psychiatry by applying the rigors of science to psychedelics, with the goal of developing available treatments to unlock healing at scale. They are developing a series of innovative product candidates targeting neurotransmitter pathways that play a key role in brain health diseases.

Company Financials

EPS

DFTX has released its 2025 Q4 earnings. EPS was reported at -0.5, versus the expected -0.51, beating expectations. The chart below visualizes how DFTX has performed over recent quarters, highlighting trends in earnings surprises.